Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2002

View Archived Issues

Versicor and Pharmacia focus on improving activity and spectrum of oxazolidinones

EMEA recommends approval for desloratadine syrup and rapidly disintegrating tablets

Lexicon validates new drug target in depression

Sepracor and 3M join forces to manufacture Xopenex HFA metered-dose inhaler

Vertex moves new drug candidate VX-799 into development for sepsis

Successful completion of clinical trial of inhaled human growth hormone

Actimmune enters phase II trial for treatment of liver fibrosis

Pilot study evaluates Natrecor in chronic heart failure outpatients

Avaden hormone replacement therapy receives French approval

Prescient NeuroPharma licenses anhydrovinblastine to Access Oncology

Major European launch announced for Kaletra

Endothelial cell-specific inhibition of protein synthesis demonstrated for tumstatin

Antisense oligonucleotide targeting Ki-ras as an approach to colorectal cancer

Specific, small-molecule inhibitor of P-selectin with antiinflammatory properties

Cell adhesion inhibitor IS-741 effective in rat model of IBD

Potent and selective OX2 receptor antagonists identified by Banyu

Gastric and cholecystokinin receptor ligands claimed in patents by James Black researchers

New Kissei compounds have potential for lowering lipids and protecting the liver

HGS and CAT form TRAIL-R1 antibody partnership

5-HT7 receptor antagonists synthesized at BMS

Solvay presents piperazine and piperidine compounds and potential uses

CD40-targeted MAb moves to clinical development at Genentech

Alexion's 5G1.1 completes phase I pilot study

DGI BioTechnologies and Novo Nordisk enter collaboration for cancer agents

CSL obtains marketing and distribution license to Angiomax in Australia

Two phase II trials of Neotrofin initiated in chemotherapy-induced neuropathy

MC-1 receives FDA approval for entry into phase II

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...